基石藥業(02616.HK):聯合含鉑化療一線治晚期非小細胞肺癌安全性良好
基石藥業(02616.HK)公布,將在美國臨床腫瘤學會(ASCO)2020年年會上,以摘要的形式公布其PD-L1單克隆抗體CS1001的CS1001-101研究最新數據。
更新數據顯示,CS1001聯合含鉑化療一線治療晚期非小細胞肺癌(NSCLC),在非鱗NSCLC和鱗狀NSCLC兩個隊列中,客觀緩解率(ORR)分別為47.6%和75%,顯示其安全性良好,未發生CS1001相關的導致患者退出研究的不良事件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.